Adenovirus E2A DNA-binding protein (E2A DBP)

The Adenovirus E2A DNA-binding protein (DBP) is a 72-kDa multifunctional protein essential for the replication of the adenovirus genome (UniProt: P03262). It functions primarily by binding to single-stranded DNA (ssDNA) with high affinity, which stabilizes the replication fork and prevents the re-annealing of the template strands during synthesis (PubMed: 2853434). E2A DBP also plays significant roles in viral gene transcription, mRNA stability, and the transition from the early to late phase of the viral life cycle (PubMed: 10666356). In the context of disease, adenovirus infections can lead to severe respiratory distress, conjunctivitis, and systemic disease in bone marrow transplant recipients (PubMed: 16188993). Because the protein is highly conserved across different adenovirus serotypes and lacks a direct human ortholog, it is considered a high-priority target for antiviral drug discovery. Although there are currently no FDA-approved drugs that specifically target E2A DBP, experimental approaches including small molecule inhibitors and antisense oligonucleotides have shown promise in preclinical models. These potential therapeutics aim to disrupt the protein's ability to multimerize or bind to DNA, thereby halting viral propagation. Monitoring viral load via PCR remains the primary biomarker for assessing the efficacy of treatments targeting adenoviral replication components.

Other names

72K DNA-binding proteinDBPEarly E2A proteinAdenoviral DBP

Inhibition of viral DNA replication by blocking the binding of E2A DBP to single-stranded DNA or preventing its multimerization.